-
Cyclic di-GMP: From Biofilm Persistence to STING
2026-09-10
Cyclic di-GMP is more than a bacterial signaling metabolite: emerging evidence positions this intracellular second messenger as a small-molecule antitoxin in biofilm persistence and a translational STING agonist for immune modulation research. This article connects mechanism, experimental design, product selection, and translational strategy.
-
BODIPY 581/591 C11 for Lipid Peroxidation
2026-09-09
BODIPY 581/591 C11 is a ratiometric fluorescent probe for lipid peroxidation detection in membranes and living cells. Its oxidation-associated red-to-green shift supports comparative oxidative stress measurement and antioxidant capacity evaluation, but it is not a universal reactive oxygen species assay.
-
EZ Cap™ Cre mRNA (m1Ψ): Workflow Guide
2026-09-09
EZ Cap™ Cre mRNA (m1Ψ) enables transient Cre recombinase expression for loxP-based gene editing, reporter activation, and functional protein studies without introducing a Cre-encoding DNA vector. This guide connects Cap 1, m1Ψ-modified mRNA design with practical delivery controls inspired by emerging extrahepatic mRNA platforms.
-
CHIR 99021 trihydrochloride for Organoids
2026-09-08
CHIR 99021 trihydrochloride is a selective GSK-3 inhibitor for tuning organoid self-renewal, differentiation, and cellular diversity. This practical guide connects dose-response design with intestinal organoid workflows, metabolic assays, and troubleshooting strategies.
-
Hyperoside–lncRNA Control of Pigeon Pea Seed Set
2026-09-08
The reference study identifies lnc187 and lnc999 as central mediators of hyperoside-induced pollen tube growth and improved pigeon pea seed production. Its mechanistic model connects flavonoid signaling with promoter regulation, protein scaffolding, and CcGRAS phosphorylation, providing a framework for studying reproductive development beyond protein-coding genes.
-
Phosbind Acrylamide SDS-PAGE Guide
2026-09-07
Phosbind Acrylamide is a phosphate-binding reagent for distinguishing phosphorylated from non-phosphorylated proteins during SDS-PAGE without phospho-specific antibodies. It is best suited to targets in the 30–130 kDa range and should be used promptly rather than stored as a working solution for extended periods.
-
ACE2 Activation and Mitochondrial Biogenesis in Sepsis
2026-09-07
A February 2024 study links ACE2 downregulation in sepsis-induced cardiomyopathy with impaired MasR–Sirt1-mediated mitochondrial biogenesis. Using Diminazene Aceturate as a pharmacological ACE2 activator and MLN-4760 as an inhibitor, the researchers connect ACE2 signaling with cardiac function, inflammation, oxidative stress, apoptosis, and mitochondrial regulation in septic mice.
-
Atrial Natriuretic Peptide: Applied Research Workflows
2026-09-05
Build reproducible workflows for blood pressure homeostasis, natriuresis mechanism studies, vascular signaling, and adipose metabolism with a research-grade ANP peptide hormone. The guide also translates a rat neuroinflammation study into practical experimental design lessons without confusing adiponectin evidence with direct evidence for atrial natriuretic peptide.
-
SIS3: Reading TGF-β/SMAD3 Causality
2026-09-04
SIS3, a selective Smad3 inhibitor, can do more than suppress TGF-β responses. This article explains how to use SIS3 to distinguish pathway causality, transcriptional feedback, and disease-relevant phenotypes across cancer and fibrosis research.
-
CAMLs in Blood: Phenotypes and Clinical Utility
2026-09-04
The reference study reframes circulating cancer-associated macrophage-like cells as phagocytic polyploid giant cancer macrophages with potential clinical relevance, rather than inert cellular debris. In a prospective, multicenter cohort, these cells correlated with progression and disease spread and displayed self-renewal, proangiogenic, and mixed-lineage features that may help explain pre-metastatic niche formation.
-
Gemcitabine and the Biomarker Logic of Chemosensitivity
2026-09-03
Gemcitabine is more than a DNA synthesis inhibitor: it is a controllable perturbation for connecting replication stress, checkpoint signaling, apoptosis, and chemotherapy resistance. This article translates findings on GPX3 and JNK/c-Jun signaling in pancreatic cancer into a practical framework for DNA damage response assays, apoptosis assays, and biomarker-led cancer research. It also explains how Gemcitabine SKU A8437 can support a more informative validation strategy than viability testing alone.
-
Sumatriptan Succinate: Applied Research Workflows
2026-09-03
Build reproducible migraine, receptor-signaling, inflammation, and metabolism assays with Sumatriptan Succinate. This guide translates pediatric emergency-care evidence into practical bench workflows while separating validated observations from exploratory protocol recommendations.
-
2-APB Calcium Signaling: Workflows & Troubleshooting
2026-09-02
Use 2-APB to separate IP3 receptor–driven calcium release from store-operated entry, TRPC activity, and downstream injury phenotypes. This practical workflow connects live-cell calcium assays with oxidative stress and cardiovascular research while emphasizing concentration, vehicle, and interpretation controls.
-
HBV Capsid Phosphorylation by Phosphate-Affinity SDS-PAGE
2026-09-02
Culhane and colleagues describe a reproducible workflow for purifying recombinant hepatitis B virus capsids from HepG2 cells and comparing their phosphorylation states by phosphate-affinity SDS-PAGE. The protocol combines sucrose-gradient ultracentrifugation, capsid integrity checks, and Phosbind acrylamide-based mobility analysis to provide a practical, semi-quantitative view of global capsid phosphorylation.
-
Fisetin, Ferroptosis, and Neuroprotection After TBI
2026-09-01
Yang et al. show that fisetin reduces neurological injury, oxidative stress, and ferroptosis-associated changes in mouse and cell models of traumatic brain injury, with PI3K/AKT/NRF2 signaling implicated in the response. The study supports a multi-readout strategy for examining ferroptosis after TBI while highlighting the need to distinguish pharmacological pathway modulation from definitive causal proof.